Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in Type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents (original) (raw)

References

1. Fabrykant M (1957) Favorable effect of supplemental Orinase in insulin-treated labile diabetes. Metabolism 6: 509–517
   PubMed Google Scholar
2. Lazarus SS, Volk BW (1959) Physiological basis of the effectiveness of combined insulin-tolbutamide. Ann NY Acad Sci 82: 590–602
   PubMed Google Scholar
3. De Fronzo RA (1988) The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37: 667–687
   PubMed Google Scholar
4. Yalow RS, Black H, Villazon M, Berson SA (1960) Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 9: 356–362
   PubMed Google Scholar
5. Lebovitz HE, Feinglos MN (1978) Sulfonylurea drugs: Mechanisms of antidiabetic action and therapeutic usefulness. Diabetes Care 1: 189–198
   PubMed Google Scholar
6. Lebovitz HE, Feinglos MN, Bucholtz HK, Lebovitz FL (1977) Potentiation of insulin action: a probable mechanism for the antidiabetic action of sulfonylurea drugs. J Clin Endocrinol Metab 45: 601–604
   PubMed Google Scholar
7. De Fronzo RA, Simonson DC (1984) Oral sulfonylurea agents suppress hepatic glucose production in non-insulin dependent diabetic individuals. Diabetes Care 7 [Suppl 1]: 72–80
   Google Scholar
8. Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG (1982) Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5: 353–363
   PubMed Google Scholar
9. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222–234
   PubMed Google Scholar
10. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM (1984) Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33: 634–642
    PubMed Google Scholar
11. Del Prato S, Ferrannini E, De Fronzo RA (1986) Evaluation of insulin sensitivity in man. In: Clarke WL, Larner J, Pohl SL (eds) Methods in diabetes research. Clinical methods, vol II. Wiley & Sons, New York, pp 36–76
    Google Scholar
12. Del Prato S, Nosadini R, Tiengo A, Tessari P, Avogaro A, Trevisan R, Valerio A, Muggeo M, Cobelli C, Toffolo G (1983) Insulin-mediated glucose disposal in type 1 diabetes: evidence for insulin resistance. J Clin Endocrinol Metab 57: 904–910
    PubMed Google Scholar
13. Ferrannini E, Del Prato S, De Fronzo RS (1986) Glucose kinetics. Tracer methods. In: Clarke WL, Larner J, Pohl SL (eds) Methods in diabetes research. Clinical methods, vol II. Wiley & Sons, New York, pp 108–141
    Google Scholar
14. Shimizu S, Inoue E, Tani Y, Yamada H (1979) Enzymatic microdetermination of serum free fatty acids. Anal Biochem 98: 341–345
    PubMed Google Scholar
15. Groop L, Harno K, Tolppanen E-M (1984) The combination of insulin and sulfonylurea in the treatment of secondary drug failure in patients with type II diabetes. Acta Endocrinol 106: 97–101
    PubMed Google Scholar
16. Bieger WP, Dlugosch R, Rettenmeier A, Holler HD, Bert H, Schwarz W, Fiehn W, Merkt J, Weiker H (1984) Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic effect. Klin Wochenschr 62: 631–639
    PubMed Google Scholar
17. Lardinois CK, Liu GC, Reaven GM (1985) Glyburide in non-insulin-dependent diabetes. Its therapeutic effect in patients with disease poorly controlled by insulin alone. Arch Intern Med 145: 1028–1032
    Article PubMed Google Scholar
18. Kyllastinen M, Groop L (1985) Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Ann Clin Res 17: 100–104
    PubMed Google Scholar
19. Groop L, Harno K, Nikkila EA, Pelkonen R, Tolppanen E-M (1985) Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. Acta Med Scand 217: 33–39
    PubMed Google Scholar
20. Allen TB, Feinglos TM, Lebovitz HE (1985) Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea. Arch Intern Med 145: 1900–1903
    Article PubMed Google Scholar
21. Quatraro A, Consoli G, Ceriello A, Giugliano D (1986) Combined insulin and sulfonylurea therapy in non-insulin-dependent diabetics with secondary failure to oral drugs: a one year follow-up. Diabete Metab 12: 315–318
    PubMed Google Scholar
22. Longnecker MP, Elsenhans V, Leiman S, Owen O, Boden G (1986) Insulin and sulfonylurea agent in non-insulin-dependent diabetes mellitus. Arch Intern Med 146: 673–676
    Article PubMed Google Scholar
23. Mauerhoff T, Ketelslegers JM, Lambert AE (1986) Effect of glibenclamide in insulin-treated diabetic patients with residual insulin secretion. Diabete Metab 12: 34–38
    PubMed Google Scholar
24. Schwartz SL, Fisher JS, Kipnes MS, Boyle M (1987) Effects of short-term insulin therapy upon therapeutic response to glipizide. Am J Med 83 [Suppl 3 A]: 22–30
    Article Google Scholar
25. Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ (1987) The addition of glipizide to insulin therapy in Type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol 116: 364–372
    PubMed Google Scholar
26. Schade DS, Mitchell WJ, Griego G (1987) Addition of sulfonylurea to insulin treatment in poorly controlled type II diabetes. A double blind, randomized clinical trial. JAMA 257: 2441–2445
    PubMed Google Scholar
27. Simonson DC, Del Prato S, Castellino P, Groop L, De Fronzo RA (1987) Effect of glyburide on glycemic control, insulin requirement, and glucose metabolism in insulin-treated diabetic patients. Diabetes 36: 136–146
    PubMed Google Scholar
28. Reich A, Abraira C, Lawrence AM (1987) Combined glyburide and insulin therapy in type II diabetes. Diab Res 6: 99–104
    Google Scholar
29. Holman RR, Steemson J, Turner RC (1987) Sulphonylurea failure in type 2 diabetes: treatment with basal insulin supplement. Diabetic Med 4: 457–462
    PubMed Google Scholar
30. Gutniak M, Karlander S-V, Efendic S (1987) Glyburide decreases insulin requirement, increases Beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of shortand long-term combined treatment in secondary failure to sulfonylurea. Diabetes Care 10: 545–554
    PubMed Google Scholar
31. Lins P-E, Lundblad S, Persson-Trotzig E, Adamson U (1988) Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with secondary failure to sulfonylurea therapy. Acta Med Scand 223: 171–179
    PubMed Google Scholar
32. Stenman S, Groop P-H, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L (1988) Effects of the combination of insulin and glibenclamide in Type 2 (non-inslulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 31: 206–213
    PubMed Google Scholar
33. Iavicoli M, Cucinotta D, De Mattia G, Lunetta M, Morsiani M, Pontiroli AE, Pozza G (1988) Blood glucose control and insulin secretion improved with combined therapy in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. Diabetes Med 5: 849–855
    Google Scholar
34. Clarke WL, Haymond M, Santiago J (1980) Overnight basal insulin requirements in fasting insulin-dependent diabetics. Diabetes 29: 78–80
    PubMed Google Scholar
35. Bolli GB, Gerich JE (1984) The “dawn phenomenon”: a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 300: 746–750
    Google Scholar
36. Hamelbeck H, Lein W, Zoltobrocki M, Schoffling K (1982) Glibenclamid-Insulin-Kombinationsbehandlung beim Sekundarversagen der Sulfonylharnstoff-Therapie. Dtsch Med Wochenschr 107: 1581–1583
    PubMed Google Scholar
37. Eaton RP, Allen RC (1981) Tolbutamide reverses insulin-resistant diabetes. Diabetes Care 4: 299–304
    PubMed Google Scholar
38. De Fronzo RA, Binder C, Wahren J, Felig P, Ferrannini E, Faber OK (1981) Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. Acta Endocrinol 98: 81–85
    PubMed Google Scholar
39. Meglasson MD, Matschinsky FM (1986) Pancreatic islet glucose metabolism and regulation of insulin secretion. Diabet Metab Res 2: 163–214
    Google Scholar
40. Leahy JL, Bonner Weir S, Weir GC (1984) Abnormal glucose regulation of insulin secretion in models of reduced B-cell mass Diabetes 33: 667–673
    PubMed Google Scholar
41. Groop L, Bonadonna R, Del Prato S, Ratheiser K, Zyck K, Ferrannini E, De Fronzo RA (1989) Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84: 205–213
    PubMed Google Scholar
42. Ferrannini E, Barret E, Bevilacqua S, De Fronzo RA (1983) Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72: 1737–1747
    PubMed Google Scholar
43. Blumenthal SA (1983) Stimulation of gluconeogenesis by palmitic acid in rat hepatocytes: evidence that this effect can be dissociated from provision of reducing equivalents. Metabolism 32: 971–976
    Article PubMed Google Scholar
44. Taskinen M-R, Sane T, Helve E, Karonen S-L, Nikkila EA, Yki-Jarvinen H (1989) Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes 38: 580–588
    PubMed Google Scholar
45. Riddle MC (1985) New tactics for type 2 diabetes: regimens based on intermediate-long acting insulin taken at bed time. Lancet 1: 192–195
    Article PubMed Google Scholar

Download references